Physician profile
Blane Mire
NPI 1326082397
$8,405.74
in general payments reported to CMS, 2019-2025
34 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,389 · 2020: $1,786 · 2021: $1,704 · 2022: $1,377 · 2023: $657 · 2024: $354 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.77 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $992.12 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $744.03 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.40 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $689.53 | 2020-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $555.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $542.35 | 2019-2025 | Repatha, Otezla |
| Novo Nordisk INC | $512.94 | 2019-2021 | |
| Astellas Pharma US INC | $508.17 | 2019-2025 | Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals LP | $482.03 | 2019-2022 | |
| Abbvie INC. | $465.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $409.85 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $404.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $379.23 | 2019-2025 | Trelegy Ellipta, Fluarix Quadrivalent, Shingrix |
| Allergan, INC. | $216.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $127.78 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $104.05 | 2019 | |
| Abbott Laboratories | $100.97 | 2022 | |
| Sanofi Pasteur INC. | $58.04 | 2019-2020 | |
| Amarin Pharma, INC. | $54.85 | 2019-2020 | |
| Edwards Lifesciences Corporation | $45.10 | 2022 | |
| Dexcom, INC. | $43.60 | 2021 | |
| Biogen, INC. | $36.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.12 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.81 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $20.45 | 2022 | |
| Csl Behring | $18.36 | 2025 | Andembry |
| Abiomed | $16.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.07 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $15.23 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $14.86 | 2019 | |
| Radius Health, INC. | $13.71 | 2019 | |
| Medtronic, INC. | $12.77 | 2021 | |
| Braintree Laboratories, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blane Mire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.